PDF(Pubmed)
Abstract：
UNASSIGNED: Endometrial stromal sarcoma (ESS) is a rare tumor that remains a diagnostic and therapeutic challenge to physicians worldwide. The metastatic setting implies a poor prognosis, with a 5-year survival rate below 40%. Patients with advanced-stage high-grade ESS (HG-ESS) have limited therapeutic options, often involving various chemotherapy regimens.
UNASSIGNED: This report depicts the case of a 47-year-old female diagnosed with HG-ESS. She underwent several lines of treatment starting with radiotherapy and brachytherapy, followed by multiple lines of treatment including trabectedin over several months. After retreatment with trabectedin and achieving disease stabilization for 10 months, treatment was optimized by trabectedin combined with radiotherapy, leading to stable disease that is still ongoing and lasts for over 17 months.
UNASSIGNED: Our case underscores the challenging nature of treating patients with HG-ESS and highlights the safety of long-term retrial with trabectedin, coupled with radiotherapy administration. This approach maintained a durable stable disease response in the metastatic setting.
UNASSIGNED: This report depicts the case of a 47-year-old female diagnosed with HG-ESS. She underwent several lines of treatment starting with radiotherapy and brachytherapy, followed by multiple lines of treatment including trabectedin over several months. After retreatment with trabectedin and achieving disease stabilization for 10 months, treatment was optimized by trabectedin combined with radiotherapy, leading to stable disease that is still ongoing and lasts for over 17 months.
UNASSIGNED: Our case underscores the challenging nature of treating patients with HG-ESS and highlights the safety of long-term retrial with trabectedin, coupled with radiotherapy administration. This approach maintained a durable stable disease response in the metastatic setting.
摘要：
子宫内膜间质肉瘤（ESS）是一种罕见的肿瘤，对全世界的医生来说仍然是诊断和治疗的挑战。转移背景意味着预后不良，5年生存率低于40%。晚期高级别ESS（HG-ESS）患者的治疗选择有限，通常涉及各种化疗方案。
■本报告描述了一名47岁女性被诊断为HG-ESS的病例。她从放疗和近距离放射治疗开始接受了几行治疗，随后在几个月内进行包括trabectedin在内的多行治疗。用trabectedin再治疗并达到疾病稳定10个月后，曲贝替丁联合放疗优化治疗方案，导致疾病稳定，这种疾病仍在持续，持续超过17个月。
我们的案例强调了使用HG-ESS治疗患者的挑战性，并强调了使用trabectedin进行长期重审的安全性，再加上放疗。这种方法在转移性环境中保持了持久稳定的疾病反应。
■本报告描述了一名47岁女性被诊断为HG-ESS的病例。她从放疗和近距离放射治疗开始接受了几行治疗，随后在几个月内进行包括trabectedin在内的多行治疗。用trabectedin再治疗并达到疾病稳定10个月后，曲贝替丁联合放疗优化治疗方案，导致疾病稳定，这种疾病仍在持续，持续超过17个月。
我们的案例强调了使用HG-ESS治疗患者的挑战性，并强调了使用trabectedin进行长期重审的安全性，再加上放疗。这种方法在转移性环境中保持了持久稳定的疾病反应。
